Kedrion Statement on the novel Coronavirus | Kedrion
You are now leaving the Kedrion website. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES
NEWS / CORPORATE / .........

CORPORATE - 24-03-2020

Kedrion Statement on the novel Coronavirus

In accordance with international, national and local authority guidelines, Kedrion has acted immediately in dealing with the epidemiological emergency linked to the spread of the new Coronavirus (SARS-CoV-2), and has taken all necessary measures to safeguard the health and safety of its employees and guarantee continuation of business activities.

Paolo Marcucci, Chairman & CEO has stated:  “As is our duty Kedrion continues to do its utmost to combine the need to safeguard the health of our workers and their families with production and the quality of our products.  Our drugs are essential to the life of those who use them and who, in many cases, do not have adequate alternative therapies: now more than ever it is our duty and honor to guarantee supply to patients.”

Moreover, in those countries worse-effected, such as Italy, employees have been encouraged to work from home as far as possible, and work-related travel has been reduced to a minimum; an existing, consolidated use of digital technology for long-distance communication and cooperation has made it easier to adopt these changes. All competent authority guidelines regarding social distancing and hygiene-health measures, aimed at containing the impact and spread of this epidemic, have been encouraged and implemented scrupulously throughout our plants

With regards to the safety of plasma derivatives, Kedrion upholds the position taken on many occasions by the international medical-scientific community and by the major associations in this sector, first among them the Plasma Protein Therapeutics Association (PPTA), by underlining again that, based on the current knowledge, there is no scientific evidence to suggest that the SARS-CoV-2 outbreak is a concern for the safety of plasma protein therapies. The stringent controls on plasma donors and on the raw material at source, and the established processes of virus inactivation and removal during manufacturing of plasma-derived products, guarantee significant safety margins even against this virus. 

Obviously Kedrion continues to follow the development of the situation in all countries very closely and, based on the epidemiological development of the illness and the indications of the competent authorities, could update the measures taken to date.

For more information please contact: pressoffice@humanked.com